{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:49:39Z","timestamp":1794512979764,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["PB-PG-1217-20011"],"award-info":[{"award-number":["PB-PG-1217-20011"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013374","name":"NIHR School for Primary Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.lanepe.2022.100579","type":"journal-article","created":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T20:03:37Z","timestamp":1676232217000},"page":"100579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-335X","authenticated-orcid":false,"given":"Julie","family":"Ashworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1227-2703","authenticated-orcid":false,"given":"Ram","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2566-3527","authenticated-orcid":false,"given":"James","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Harrisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Whittle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian D.","family":"Mallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lanepe.2022.100579_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.lanepe.2022.100579_bib2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/pm\/pnw351","article-title":"Impact of unrestricted access to pregabalin on the use of opioids and other CNS-active medications: a cross-sectional time series analysis","volume":"18","author":"Kwok","year":"2017","journal-title":"Pain Med"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100579_bib3","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101120","article-title":"Pregabalin prescribing patterns in Australian general practice, 2012-2018: a cross-sectional study","volume":"5","author":"Schaffer","year":"2021","journal-title":"BJGP Open"},{"issue":"20","key":"10.1016\/j.lanepe.2022.100579_bib4","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.2018.12358","article-title":"Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017","volume":"320","author":"Montastruc","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.lanepe.2022.100579_bib5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A\u00a0clinical overview of off-label use of gabapentinoid drugs","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.lanepe.2022.100579_bib6","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.joca.2019.06.008","article-title":"Trends in gabapentinoid prescribing in patients with osteoarthritis: a United Kingdom national cohort study in primary care","volume":"27","author":"Appleyard","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100579_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: a systematic review update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.lanepe.2022.100579_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A\u00a0decade of gabapentinoid misuse: an analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.lanepe.2022.100579_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.04.028","article-title":"Profiles of pregabalin and gabapentin abuse by postmortem toxicology","volume":"241","author":"Hakkinen","year":"2014","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.lanepe.2022.100579_bib11","author":"Gov"},{"issue":"8","key":"10.1016\/j.lanepe.2022.100579_bib12","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1111\/bcp.14727","article-title":"Trends in new prescription of gabapentinoids and of coprescription with opioids in the 4 nations of the UK, 1993-2017","volume":"87","author":"Rahman","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.lanepe.2022.100579_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"7","key":"10.1016\/j.lanepe.2022.100579_bib14","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1097\/j.pain.0000000000000557","article-title":"Trends in long-term opioid prescribing in primary care patients with musculoskeletal conditions: an observational database study","volume":"157","author":"Bedson","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.lanepe.2022.100579_bib16","doi-asserted-by":"crossref","first-page":"l2147","DOI":"10.1136\/bmj.l2147","article-title":"Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden","volume":"365","author":"Molero","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2022.100579_bib17","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.lanepe.2022.100579_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.lanepe.2022.100579_bib19","doi-asserted-by":"crossref","first-page":"m114","DOI":"10.1136\/bmj.m114","article-title":"Gabapentinoids: has reclassification really solved the problem?","volume":"368","author":"Mahase","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.lanepe.2022.100579_bib20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/pds.4320","article-title":"A\u00a015-year overview of increasing tramadol utilisation and associated mortality and the impact of tramadol classification in the United Kingdom","volume":"27","author":"Chen","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.lanepe.2022.100579_bib21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MLR.0000000000001719","article-title":"Prescription patterns of adjuvant pain medications following an opioid supply restriction law: an interrupted time series analysis","volume":"60","author":"Shen","year":"2022","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100579_bib22","first-page":"83","article-title":"Trends, patient and prescriber characteristics in gabapentinoid use in a sample of United States ambulatory care visits from 2003 to 2016","volume":"9","author":"Zhou","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"10.1016\/j.lanepe.2022.100579_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bja.2020.05.017","article-title":"Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland","volume":"125","author":"Torrance","year":"2020","journal-title":"Br J Anaesth"},{"issue":"4","key":"10.1016\/j.lanepe.2022.100579_bib24","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/rheumatology\/keaa586","article-title":"Co-prescription of gabapentinoids and opioids among adults with and without osteoarthritis in the United Kingdom between 1995 and 2017","volume":"60","author":"Yu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.lanepe.2022.100579_bib25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S1474-4422(13)70193-5","article-title":"Combination pharmacotherapy for management of chronic pain: from bench to bedside","volume":"12","author":"Gilron","year":"2013","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.lanepe.2022.100579_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.lanepe.2022.100579_bib27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.7326\/M18-1136","article-title":"Pregabalin and the risk for opioid-related death: a nested case-control study","volume":"169","author":"Gomes","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.lanepe.2022.100579_bib29","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bcp.15028","article-title":"Association between opioid-related deaths and persistent opioid prescribing in primary care in England: a nested case-control study","volume":"88","author":"Chen","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.lanepe.2022.100579_bib30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40266-014-0202-4","article-title":"Antiepileptics for post-herpetic neuralgia in the elderly: current and future prospects","volume":"31","author":"Pickering","year":"2014","journal-title":"Drugs Aging"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776222002757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776222002757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:55:58Z","timestamp":1763009758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776222002757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":27,"alternative-id":["S2666776222002757"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2022.100579","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2022.100579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100579"}}